Fabrication of drug-eluting covered stents with micropores and differential coating of heparin and FK506.
To reduce in-stent restenosis rates, we developed a novel drug-eluting covered stent with a microporous elastometric covered film, in which its luminal surface was flat and immobilized with heparin for anticoagulation and its outer surface immobilized with FK506 to prevent neointimal hyperplasia. One month after implantation into the bilateral common carotid arteries, all stented arteries were patent and the luminal surfaces were fully covered with a confluent of endothelial cells irrespective of the drug immobilization. In the control group, which consisted of covered stents without drug immobilization, intensive inflammatory cells adjacent to the stents and neointimal hyperplasia, indicating vascular injury, were observed. In contrast, in the developed drug-eluting stents, only a few inflammatory cells around the stent strut and covered film were observed, and there was no significant neointimal thickening.
Nakayama
Yasuhide
Y
Department of Bioengineering, National Cardiovascular Center Research Institute, 5-7-1 Fujishiro-dai, Osaka 565-8565, Suita, Japan. nakayama@ri.ncvc.go.jp
Nishi
Shogo
S
Ishibashi-Ueda
Hatsue
H
D000818:Animals; D000925:Anticoagulants / Q000008:administration & dosage*; D017536:Carotid Artery, Common / Q000473:pathology / Q000601:surgery*; D016893:Carotid Stenosis / Q000517:prevention & control*; D020724:Elastomers / Q000627:therapeutic use; D006493:Heparin / Q000008:administration & dosage*; D006965:Hyperplasia / Q000473:pathology / Q000517:prevention & control; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008851:Micropore Filters; D023421:Models, Animal; D011474:Prosthesis Design; D011817:Rabbits; D055502:Secondary Prevention; D015607:Stents; D016559:Tacrolimus / Q000008:administration & dosage*; D017539:Tunica Intima / Q000473:pathology
D000925:Anticoagulants; D020724:Elastomers; D007166:Immunosuppressive Agents; D006493:Heparin; D016559:Tacrolimus